Global Factor VIII Deficiency Treatment Market 2017-2021

Factor VIII deficiency treatment market size & share

According to Technavio’s analyst, the global factor VIII deficiency treatment market is anticipated to grow at a steady rate and post a CAGR of close to 6% during the forecast period. The increasing adoption rate of prophylactic drugs will drive the growth prospects for the global factor VIII deficiency treatment market until the end of 2021. 

Get A Free Sample

Factor VIII deficiency treatment market status based on geography

In terms of geography, the Americas accounted for the majority market share during 2016 and will continue to dominate the factor 8 deficiency treatment market for the next four years. Some of the major factors responsible for the market’s growth in the region is the growing number of new product launches and increasing amount of investment in manufacturing and production facilities by various vendors.

Factor VIII deficiency treatment market worth: Competitive landscape and key vendors

The global factor VIII deficiency treatment market is highly competitive and diversified due to the presence of a large number of regional and international vendors across the globe. It has been observed that these vendors in the factor 8 deficiency treatment market are increasingly competing against each other based on factors such as aggressive pricing, novel products such as extended half-life therapies, gene therapy products, and prophylactic drugs.

Key vendors in the factor VIII deficiency treatment market

• Bayer HealthCare
• CSL
• Grifols
• Novo Nordisk
• Pfizer
• Shire

Factor VIII deficiency treatment market segmentation by type of disease application

• Hemophilia A drugs
• Hemophilia A inhibitors treatment
• Von Willebrand disease treatment

The global hemophilia A drugs market segment accounted for the majority market share during 2016 and will continue to dominate the factor 8 deficiency treatment market for the next four years. Some of the major factors responsible for the market segment's growth is the growing incidence of hemophilia A, the development of novel drugs with extended action, and the increased adoption of prophylactic treatment. Additionally, growing demand for novel recombinant extended half-life products, the emergence of monoclonal antibodies and gene therapy products, and launch of plasma-derived products for recombinant factor VIII at low costs, will also further drive the growth of the factor VIII deficiency treatment market.

Factor VIII deficiency treatment market segmentation by type of disease management 

• Prophylaxis
• On-demand
• Inhibitor

The prophylaxis segment accounted for the majority market share during 2016 and will continue to dominate the factor 8 deficiency treatment market during the forecasted period. One of the major factors responsible for the market segment's growth is the cost-effectiveness of prophylactic treatment in comparison to on-demand treatment.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global factor VIII deficiency treatment market?
• What are the key market trends impacting the growth of the global factor VIII deficiency treatment market?
• What are the challenges to market growth?
• Who are the key vendors in the global factor VIII deficiency treatment market?
• What are the market opportunities and threats faced by the vendors in the global factor VIII deficiency treatment market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global factor VIII deficiency treatment market?

Technavio also offers customization on reports based on specific client requirement.

Related reports

• Global Hemophilia Drugs Market 2016-2020
• Global Blood Coagulation Analyzer Market 2016-2020
• Global Alpha-1 Antitrypsin Drugs Market 2016-2020